Cite
APA Citation
Campos, J. A. S., Arbetter, D., Montgomery, H., Richard Hobbs, F. D., Padilla, F., Kim, K., Streicher, K., Templeton, A., Viani, R. M., & Esser, M. T. (n.d.). 1918. Impact of the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) on the Severity and Progression of COVID-19 Symptoms in the Phase 3 TACKLE Trial. Open forum infectious diseases, 9, . http://access.bl.uk/ark:/81055/vdc_100174898611.0x000008